Text

Purpose: To present Week (W) 24 results from the SPECTRUM study on the real-world effectiveness and safety of aflibercept 8 mg in patients with treatment-naïve (TN) and previously treated (PT) neovascular age-related macular degeneration (nAMD).

Methods: SPECTRUM (NCT06075147) is an ongoing, global, 24-month, prospective observational study. Patients (TN or PT) with nAMD aged ≥50 years, who were prescribed aflibercept 8 mg prior to study start, were eligible. All treatment decisions are per physician discretion and local practice. The W24 analysis (visit closest to 180 [150–210] days after baseline [BL]) included the first ~150 patients enrolled globally in each nAMD cohort. Analyses were exploratory; missing values were imputed with the last observation carried forward approach. The latest data-cuts were used (April 9, 2025 and January 05, 2026 for the TN and PT nAMD cohorts).

Results: The TN nAMD (n=141) and PT (n=148) nAMD cohorts had a mean age of 80.8 and 79.5 years. In the PT nAMD cohort, 71.0% of patients had previously received aflibercept 2 mg; the median time from nAMD diagnosis was 33.8 months. At W24 in the TN and PT nAMD cohorts, the mean (95% CI) change in visual acuity (VA) from BL was +3.5 (1.1, 5.8) and -0.9 (-2.6, 0.8) letters (BL: 61.6 and 63.1 letters), with a mean change in central retinal thickness (CRT) of -119 (-146, -92) and -35 (-54, -16) µm (BL: 365 and 324 µm). Patients in the TN and PT nAMD cohorts received a mean±SD of 4.7±1.2 and 4.5±1.6 injections up to Day 210 from BL. No new safety concerns were identified.

Conclusions: W24 results from the SPECTRUM study of aflibercept 8 mg confirm improvements in VA and CRT in the TN nAMD cohort and stable VA and improved CRT in the PT nAMD cohort; no new safety concerns were identified.